6-Bromo-3-Hydroxypyrazine-2-Carboxamide CAS 259793-88-9 Puritas ≥99.0% Favipiravir Intermedia COVID-19 Featured Image

6-Bromo-3-Hydroxypyrazine-2-Carboxamide CAS 259793-88-9 Munditia ≥99.0% Favipiravir COVID-19

Description:

Nomen: 6-Bromo-3-Hydroxypyrazine-2-Carboxamide

CAS: 259793-88-9

Puritas: ≥99.0%

Intermedia Favipiravir ( CAS 259793-96-9 ) in curatione Influenzae virus et COVID-19 .

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Manufacturer cum High puritate et stabulo Quality
Commercial Supple Favipiravir et intermedia:
Favipiravir CAS 259793-96-9
2-Aminopropanediamide CAS 62009-47-6
Diethyl Aminomalonatum Hydrochloridum CAS 13433-00-6
3,6-Dichloropyrazinum-2-Carbonitrile CAS 356783-16-9
3,6-Difluoropyrazine-2-Carbonitrile CAS 356783-28-3
6-Fluoro-3-Hydroxypyrazine-2-Carbonitrile CAS 356783-31-8
6-Bromo-3-Hydroxypyrazine-2-Carboxamide CAS, 259793-88-9
3-Hydroxypyrazine-2-Carboxamide CAS 55321-99-8

Chemical Properties:

Nomen chemicum	6-Bromo-3-Hydroxypyrazine-2-Carboxamide
Synonyma	Favipiravir Medius;Favipiravir immunditia 4
CAS Number	259793-88-9
CATTUS Number	RF-PI296
Stock Status	In Stock, Productio Ascendite usque ad Centum chiliogrammata
Formulae hypotheticae	C5H4BrN3O2
M. Pondus	218.01
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Lux Yellow ut Brown pulveris
Lepidium sativum	IR, HPLC
Damnum in Siccatio	≤1.0%
Residere in Ignition	≤0.20%
una immunditia	≤0.50%
Totalis immunditias	≤1.0%
Metalla gravis	≤20ppm
RELICTUM Solvents	Occursum specificationem
Test Standard	Enterprise Standard
Consuetudinem	Favipiravir (CAS, 259793-96-9)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.

commoda:

FAQ:

Applicatio:

6-Bromo-3-Hydroxypyrazine-2-Carboxamide (CAS 259793-88-9) est typice intermedius in synthesi 6-Bromo-3-Hydroxypyrazini-2-Carboxamide commercium nomine Favipiravir (CAS 259793-96-9) in the treatment of Influenza virus infectiones.Iter oeconomicum practicum et privignum ad Favipiravir.Favipiravir productum investigationis relatae est COVID19 in curatione aegrorum cum COVID-19 commendata a WHO.Favipiravir, etiam T-705 vel Avigan notus, medicamentum antivirale augetur a Toyama Chemical (Fujifilm Group) Iaponiae cum actione contra multa RNA virus.Favipiravir venalicium in Iaponia mense Martio 2014 probatus est et ad usum antiviralem influentiae A et B. Praeter virus influentiae, medicamentum etiam ostendit bonam actionem antiviralem variis RNA virus, sicut virus Ebola, virus arenae; Virus Bunia, virus rabies etc. Mense Februario 2020 Favipiravir in Sinis studebat propter experimentalem curationem COVID-19 emergentis (Novel Coronavirus) morbum et eventus prosperos ostendit.